Skip to content
Menu

BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $41

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $40 to $41.

BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $40 to $41.

Read at benzinga.com

← All stock news